Mutation and control of the human immunodeficiency virus.
We examine the dynamics of infection by the human immunodeficiency virus (HIV), as well as therapies that minimize viral load, restore adaptive immunity, and use minimal dosage of anti-HIV drugs. Virtual therapies for wild-type infections are demonstrated; however, the HIV infection is never cured, requiring continued treatment to keep the condition in remission. With high viral turnover and mutation rates, drug-resistant strains of HIV evolve quickly. The ability of optimal therapy to contain drug-resistant strains is shown to depend upon the relative fitness of mutant strains.
Stengel
Robert F
RF
Department of Mechanical and Aerospace Engineering, Princeton University Princeton, P.O. Box CN5263, Princeton, NJ 08544-5263, USA. stengel@princeton.edu
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D006678:HIV / Q000187:drug effects* / Q000472:pathogenicity* / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008962:Models, Theoretical; D016296:Mutagenesis / Q000276:immunology; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors